PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

CompletedOBSERVATIONAL
Enrollment

820

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
DEVICE

MammaPrint

All subjects

Trial Locations (53)

11042

North Shore/Monter Cancer Center, Lake Success

14203

Roswell Park Cancer Center, Buffalo

15243

St. Clair Hospital, Pittsburgh

19047

St. Mary Medical Center, Langhorne

21225

MedStar Harbor Hospital, Baltimore

21237

Harry & Jeanette Weinberg Cancer Institute at Franklin Square, Baltimore

21502

Western Maryland Health System, Cumberland

24501

Lynchburg Hematology Oncology Clinic, Lynchburg

29406

Charleston Cancer Center, Charleston

30033

Dekalb Medical Center, Decatur

30501

Northeast Georgia Medical Center, Gainesville

30607

Northeast Georgia Cancer Care, Athens

32114

Halifax Health Center for Oncology, Daytona Beach

33316

Broward Health Medical Center, Fort Lauderdale

33462

The Breast Institute at JFK Medical, Atlantis

33907

Regional Breast/21st Century Oncology, Fort Myers

37203

Nashville Breast Center, Nashville

37909

Knoxville Comprehensive Breast Center, Knoxville

38501

Cookeville Regional Medical Center, Cookeville

46601

Northern Indiana Cancer Research Consortium, South Bend

47402

IU Health Bloomington, Bloomington

50702

Covenant Medical Center, Waterloo

53211

Columbia St. Mary's Cancer Center, Milwaukee

53226

Aurora Advanced Healthcare, Milwaukee

53405

Wheaton Franciscan Cancer Care - All Saints, Racine

55407

Virginia Piper Cancer Institute, Minneapolis

60007

Alexian Brothers Medical Center, Elk Grove Village

60062

Orchard Healthcare Research, Northbrook

60134

Delnor Community Hospital, Geneva

60190

CDH Cancer Center, Winfield

60426

Ingalls Memorial Hospital, Harvey

63044

St. Louis Cancer Care, Bridgeton

63117

SSM Cancer Center, St Louis

73117

University of Oklahoma, Oklahoma City

74136

Tulsa Cancer Institute, Tulsa

75230

Texas Health, Dallas

80218

Exempla Saint Joseph Hospital, Denver

91505

Providence Saint Joseph Medical Center, Burbank

92262

Comprehensive Cancer Center, Palm Springs

92705

Breastlink, Santa Ana

95403

Redwood Regional Cancer Center, Santa Rosa

98104

Swedish Cancer Institute, Seattle

Unknown

Maricopa Integrated Health System, Phoenix

Loyola University Medical Center, Chicago

Mercy Medical Center, Baltimore

Detroit Clinical Research Center, Detroit

Columbia University, New York

Hematology/Oncology Associates, Alexandria

06902

Stamford Hospital, Stamford

01805

Lahey Clinic, Burlington

02144

Mount Auburn Hospital, Cambridge

01702

MetroWest Medical Center, Framingham

01608

St. Vincent Hospital, Worcester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Agendia

INDUSTRY

NCT01617954 - PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score | Biotech Hunter | Biotech Hunter